Abstract
Respiratory syncytial virus is a virus that causes infections in lower respiratory tract among infants aged under 5 years old, older adults aged above 65 years old and populations with other potential complications. Some susceptible populations to RSV may develop pneumonia and bronchiolitis. The mechanism of RSV virus transmission is through air droplets. The burden of hospitalization causes by the infection of RSV is severe and episodic, with the prevalence mainly concentrated in winter periods. The development of vaccines against RSV virus statutes in the early 1960s, but was paused and halted due to the failure of formalin inactivated vaccine. The current study first reviewed the prevalence, structure, mechanism and development history of RSV and its vaccines, following which the present work focus on a summary of the results of clinical trials of vaccines against RSV on different groups of populations, especially those with special condition, such as older adult and pregnant women.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
